103 articles with LEO Pharma
LEO Pharma A/S Acquires Rights to Develop and Market brodalumab for Moderate-to-Severe Psoriasis Outside of Europe
New sub-licensing agreement allows LEO Pharma to help more people around the world with an additional treatment option for psoriasis
LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis
LEO Pharma Inc., a wholly owned subsidiary of LEO Pharma A/S, announced today the U.S. Food and Drug Administration (FDA) has expanded the approved indication for Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older.
LEO Pharma, a global leader in medical dermatology, announced that Gitte Aabo will step down as President and CEO after 27 years in the company, 11 of these as CEO.
LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
LEO Pharma A/S announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Management.
AMPLEXOR Announces 21st Annual BE THE EXPERT Training and Conference, Featuring Presenters from Iperion, Main 5, Guerbet, Janssen and LEO Pharma
Focusing on ‘Make Transformation Happen’, AMPLEXOR’s annual event line-up of life sciences thought leaders will present strategies and best practices to transform processes and technologies, while combatting challenges in an ever-changing regulatory landscape
New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis
LEO Pharma A/S announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI 100 score for longer than those who were treated with ustekinumab over 52 weeks.
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma and Elektrofi Expand Partnership to Co-Develop New Antibodies with the Aim of Achieving Improvements in Drug Delivery within Dermatology
LEO Pharma A/S and Elektrofi announced an expansion of the two companies’ partnership agreement to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
LEO Pharma Showcases Data in Four Disease Areas at 2019 American Academy of Dermatology Annual Meeting in Washington, D.C.
LEO Pharma A/S announced that 13 data abstracts, including seven oral presentations across atopic dermatitis, chronic hand eczema, psoriasis and actinic keratosis will be presented during the 2019 American Academy of Dermatology Annual Meeting in Washington, D.C.
LEO Pharma announced changes to its Board of Directors.
LEO Pharma A/S announced its annual results for 2018 and outlined expectations for 2019.
LEO Pharma, a global leader in medical dermatology, today announced that two of the company’s scientists have been awarded Innovation Fund Denmark’s Innovator of the Year Award 2019.
2/1/2019As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
LEO Pharma Further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine
LEO Pharma announced that Thomas Hultsch has been appointed as Head of Translational Medicine as of 28 January, 2019.
1/11/2019Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference.
LEO Pharma Strengthens Focus on Translational Medicine with the Appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor
LEO Pharma announced that Adam B. Raff has been appointed as Director and Medical Advisor in Translational Medicine as of January 28, 2019
LEO Pharma initiates phase 2b clinical studies of topical delgocitinib cream in adults for the treatment of both atopic dermatitis and chronic hand eczema
LEO Pharma A/S announces today that it has enrolled the first patients in two new phase 2b clinical studies to investigate delgocitinib, a novel topical pan-Janus kinase inhibitor (JAKi), as a monotherapy for adults with mild-to-severe atopic dermatitis (AD) as well as mild-to-severe chronic hand eczema (CHE).
11/20/2018Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.
Enstilar is now covered by the Non-Insured Health Benefits Program for Adults with Psoriasis Vulgaris
LEO Pharma Canada has announced that as of October 15th, 2018, Enstilar® has been added as a benefit through the Non-Insured Health Benefits (NIHB) Program for eligible First Nations and Inuit people across Canada.
LEO Science & Tech Hub Partners with Wearifi and Northwestern University to Develop Wearable Device for Dermatology Research
Wearifi designs and develops the world’s smallest, battery-free wearable device.